Vitamin C Supplementation Shows Promising Potential in Early Intervention for Precancerous Blood Disorders

vitamin c supplementation shows promising potential in early intervention for precancerous blood disorders

New findings from the phase 2 EVITA clinical trial suggest that vitamin C supplementation may offer significant benefits for individuals diagnosed with precancerous blood conditions and early-stage blood cancers. This randomized, double-blind, placebo-controlled study, a collaborative effort by the Van Andel Institute-Stand Up To Cancer® Epigenetics Dream Team, has illuminated a potential new avenue for cancer interception, aiming to intervene before diseases become fully established. The results, published in the prestigious American Cancer Society journal CANCER, indicate that daily oral administration of 1,000 mg of vitamin C for one year led to a reduction in adverse events during the study and its subsequent follow-up period. Furthermore, the supplementation demonstrably altered the levels of specific immune signaling molecules, known as cytokines, in patterns associated with more favorable patient outcomes. These observed changes suggest a potential role for vitamin C in modulating inflammation-related processes that are intricately involved in the proliferation and progression of abnormal blood cells. While the vitamin did not significantly alter the rate of abnormal blood cell expansion, an exploratory analysis revealed a compelling trend: participants receiving vitamin C were significantly more likely to be alive after approximately three years of follow-up compared to those who received a placebo. Scientists emphasize that this potentially life-extending benefit warrants further rigorous investigation in larger, phase 3 clinical trials.

Groundbreaking Research Explores Vitamin C as a Proactive Therapeutic Strategy

The implications of this research are particularly significant given the current landscape of managing precancerous blood disorders. These conditions, such as clonal cytopenia of undetermined significance (CCUS) and myelodysplastic syndrome (MDS), carry an elevated risk of progressing into acute myeloid leukemia (AML), a particularly aggressive and challenging form of blood cancer. For many patients diagnosed with CCUS, the current standard of care is vigilant monitoring, with no approved treatments available to prevent progression to leukemia. While MDS can be managed with stem cell transplantation, this option is often unavailable to many patients due to age or co-existing medical conditions. This leaves a critical unmet need for interventions that can actively manage or mitigate the risk of disease progression.

Dr. Peter A. Jones, Ph.D., D.Sc. (hon), a distinguished professor at Van Andel Institute and a co-corresponding author of the study, expressed considerable enthusiasm for the findings. "We are tremendously excited and cautiously optimistic that our results could one day translate into a simple way to improve care and outcomes for people with pre-leukemia disorders," Dr. Jones stated. He further elaborated on the study’s alignment with the burgeoning field of cancer interception, noting, "Our approach reflects a growing emphasis on cancer interception — intervening before cancer becomes established. We are working to build on the trial findings by exploring how exactly vitamin C interacts with pre-cancerous cells, including the idea that it may help restore normal epigenetic function in blood cells at risk of becoming leukemia."

The international research effort was spearheaded by Dr. Kirsten Grønbæk, M.D., Ph.D., a leading hematologist, professor at the University of Copenhagen, and a key member of the VAI-SU2C Epigenetics Dream Team. Dr. Grønbæk echoed the sentiment of cautious optimism, remarking, "These exciting preliminary findings lay the groundwork for a larger clinical trial to explore vitamin C as a possible way to improve patient outcomes. It is too early to make definitive recommendations based on our results, but we are hopeful that a more expansive study will provide further insights."

The EVITA Trial: A Novel Approach to Precancerous Blood Conditions

The EVITA trial itself represented a significant step forward in the investigation of vitamin C’s therapeutic potential. It enrolled 109 patients diagnosed with either CCUS or MDS. Both of these conditions are recognized as precursors to AML, a diagnosis that often carries a grim prognosis due to its aggressive nature and treatment resistance. The incidence of CCUS and related blood disorders is known to increase with age, making these conditions particularly prevalent among older adult populations.

The study’s design was meticulously crafted to minimize bias and ensure objective assessment of vitamin C’s effects. Participants were randomly assigned to one of two groups. The intervention group received 1,000 mg of vitamin C orally each day for a duration of 12 months. The control group received a placebo, carefully formulated to be indistinguishable from the vitamin C supplement in terms of appearance, taste, and smell, but devoid of any active vitamin C. This double-blind, randomized, placebo-controlled methodology is considered the gold standard in clinical research, providing the highest level of confidence in the observed results. Crucially, neither the participants nor the clinical staff involved in administering the treatments were aware of which patients were receiving vitamin C until the study’s conclusion.

The research was conducted across four reputable medical institutions: Copenhagen University Hospital-Rigshospitalet, Copenhagen University Hospital-Herlev, Aalborg University Hospital, and Keck Hospital of the University of Southern California, underscoring the collaborative and geographically diverse nature of this important study.

What distinguishes the EVITA trial from previous investigations is its pioneering role in being the first randomized, double-blind, placebo-controlled study to examine oral vitamin C specifically in patients with conditions that can precede leukemia or with lower-risk myeloid cancers. Earlier research efforts had largely focused on intravenously administered vitamin C and primarily investigated its effects on solid tumors, rather than precancerous blood disorders or early-stage blood malignancies. The EVITA trial, by contrast, evaluated a daily oral dose that is readily accessible and comparable to what is found in many over-the-counter vitamin C supplements, making its findings potentially more applicable to widespread clinical practice.

Addressing Vitamin C Deficiencies in At-Risk Populations

A critical aspect of the EVITA trial involved meticulous monitoring of participants’ vitamin C levels. Blood samples were collected at various points throughout the study to track vitamin C concentrations and to determine if supplementation effectively corrected any existing deficiencies. The findings revealed a significant prevalence of insufficient vitamin C levels, with more than half of the participants exhibiting low concentrations at the commencement of the trial. For those assigned to the vitamin C supplementation group, a notable outcome was the normalization of their blood vitamin C concentrations after initiating the treatment regimen.

The possibility of an accessible intervention like vitamin C supplementation is particularly vital for individuals living with conditions that carry the risk of developing into leukemia. In many of these situations, physicians are limited to a "watch and wait" approach, monitoring disease progression without the ability to actively prevent it. Dr. Casey O’Connell, M.D., FACP, the Lawrence and Jane Kelly Chair in Hematology at the University of Southern California and lead clinician at USC’s trial location, highlighted the profound impact of this limitation on patients. "The standard approach for patients with pre-cancer blood disorders is to monitor their blood cell counts over time. This is, understandably, very frustrating — no one wants to hear that they have a condition that increases leukemia risk but there’s nothing that can be done other than watch and wait," Dr. O’Connell explained. She added, "The EVITA trial took on this challenge by exploring vitamin C’s potential to address the underlying factors that drive leukemia development."

The Biochemical Underpinnings: Vitamin C’s Role in Cellular Regulation

The scientific investigation into vitamin C’s potential role in cancer development spans over seven decades, a period marked by evolving research methodologies and fluctuating evidence. While earlier studies often yielded inconsistent results, leading to uncertainty, recent advancements in research technologies have begun to unravel the complex mechanisms by which vitamin C influences cellular processes beyond its well-established roles in nutrition and immunity.

A key discovery has been vitamin C’s involvement in epigenetics, the study of heritable changes in gene expression that do not involve alterations to the underlying DNA sequence. Specifically, vitamin C plays a crucial role in the activity of TET2, an enzyme critical for preventing cancerous growth. TET2 functions by regulating gene expression, essentially controlling whether particular genes are switched "on" or "off." Vitamin C acts as a cofactor, supporting the normal activity of TET2, which is essential for maintaining proper gene regulation patterns within cells.

Mutations affecting the TET2 gene are frequently observed in leukemia and related blood disorders. When the normal function of TET2 is compromised due to these mutations, abnormal cells can gain an advantage, enabling them to multiply unchecked and potentially evolve into cancer. Preclinical experiments using cancer models have provided compelling evidence of vitamin C’s protective effects in this context. These studies demonstrated that vitamin C supplementation could interfere with cellular changes associated with cancer development and slow the progression of leukemia. Notably, the most pronounced effects were observed when vitamin C was introduced at an early stage, before cancer had become fully established. This observation was a significant inspiration for the concept of using vitamin C as an early intervention strategy, targeting the molecular alterations that precede the onset of leukemia.

From Pilot Studies to Phase 3 Aspirations: The Road Ahead

The EVITA trial was not an isolated endeavor but rather a logical progression of prior research. Before initiating the phase 2 trial, the VAI-SU2C Epigenetics Dream Team conducted a pilot clinical study in 2016. This initial study was designed to ascertain whether oral vitamin C supplementation could effectively increase vitamin C concentrations in the blood. The positive results from this pilot study, which confirmed the feasibility and efficacy of oral supplementation, provided the necessary foundation for the larger EVITA trial, launched in 2017.

Dr. Stine Ulrik Mikkelsen, M.D., Ph.D., the study’s first author and a clinician researcher in Dr. Grønbæk’s laboratory, emphasized the importance of this preparatory work. "This early work was critical because it offered a foundation from which to develop the present trial," she stated. "Vitamin C is important because it is involved in a range of biological functions, including the activity of enzymes that regulate normal cell function."

Researchers are currently engaged in an in-depth analysis of the extensive data collected during the EVITA trial. The goal is to gain a more profound understanding of the specific biological pathways through which vitamin C may exert its observed effects, particularly concerning the improved survival rates seen in the supplementation group.

While the findings from the EVITA trial offer a promising and exciting new direction for future research, it is imperative to reiterate that further clinical studies are essential. These larger, more comprehensive investigations will be crucial to definitively establish whether vitamin C supplementation can reliably and consistently improve outcomes for individuals living with precancerous blood disorders and early-stage blood cancers. The journey from promising preliminary results to established clinical practice is a rigorous one, demanding extensive validation through well-designed and adequately powered phase 3 trials.

The collaborative nature of this research is further highlighted by the extensive list of contributing authors from various institutions: Ali Al-Mousawi, M.D., Amalie Bach Puglisi, M.D., Anders Pommer Vallentin, M.D., Astrid Østergaard Mortensen, Heidi Naomi Ottesen, Linn Gillberg, M.Sc., Ph.D., Morten Tulstrup, M.D., M.Sc., Ph.D., Jakob Werner Hansen, M.D., Ph.D., and Mette Klarskov Andersen, M.D., D.MSc., all affiliated with the University of Copenhagen and Copenhagen University Hospital-Rigshospitalet; Zachary Madaj, M.S., Toshinori Hinoue, Ph.D., Stacey L. Thomas, Ph.D., Christine N. Isaguirre, Ryan D. Sheldon, Ph.D., Marie Adams, M.S., Ryan Burgos, and Peter W. Laird, Ph.D., from Van Andel Institute; Jakob Schmidt Jespersen, M.Sc., Ph.D., Niels Richard Hansen, M.Sc., and Jens Lykkesfeldt, Ph.D., D.MSc., of the University of Copenhagen; Stephen Baylin, M.D., associated with Johns Hopkins University and Van Andel Institute; Bo Kok Mortensen, M.D., Ph.D., of Copenhagen University Hospital-Rigshospitalet and Copenhagen University Hospital-Herlev; and Marianne Tang Severinsen, M.D., Ph.D., from Aalborg University Hospital.

The research was generously supported by funding from Van Andel Institute through the Van Andel Institute-Stand Up To Cancer® Epigenetics Dream Team, the Danish Cancer Society, and Greater Copenhagen Health Science Partners, underscoring the broad institutional commitment to advancing cancer research.